TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026
Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory milestone after the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for LEQEMBI IQLIK® (lecanemab-irmb) as a once-weekly subcutaneous initiation dose for the treatment of early Alzheimer’s disease. The approval introduces the first anti-amyloid therapy that enables patients to begin treatment at home using an autoinjector, eliminating the need for intravenous infusions during the initiation phase while providing greater flexibility throughout the treatment journey. Eisai plans to launch LEQEMBI IQLIK in the United States in late August 2026, offering patients and healthcare providers an innovative administration option that supports broader access to disease-modifying Alzheimer’s therapy. The FDA decision is supported by robust clinical evidence demonstrating that subcutaneous administration delivers exposure comparable to intravenous dosing, maintains a similar efficacy profile, and provides a generally consistent safety profile, reinforcing confidence in the new administration method.
FDA Approval Brings At-Home Alzheimer’s Treatment to Patients
The approval represents a significant advancement in Alzheimer’s care by allowing eligible patients to receive LEQEMBI IQLIK through a convenient autoinjector, with each 250 mg injection delivered in approximately 15 seconds. Patients beginning therapy will receive 500 mg once weekly as two injections, while maintenance dosing remains available following long-term treatment. Unlike traditional intravenous administration that requires hospital visits, infusion centers, nursing support, and extended monitoring, the new subcutaneous formulation enables treatment in home settings, reducing the burden on patients, caregivers, and healthcare systems. Clinical studies supporting the approval confirmed that once-weekly subcutaneous dosing achieved equivalent drug exposure and amyloid removal compared with intravenous therapy, while maintaining a comparable safety profile. Injection-site reactions were generally localized and manageable, supporting the feasibility of long-term home administration. According to patient usability research, 94% of patients and caregivers found the LEQEMBI IQLIK autoinjector easy to use, highlighting its potential to improve adherence and patient satisfaction throughout Alzheimer’s treatment.
Clinical Data Supports Flexible Alzheimer’s Care
The FDA approval is based on comprehensive clinical evidence from the Phase 3 Clarity AD Long-Term Extension studies, which demonstrated that subcutaneous LEQEMBI provides efficacy and biomarker outcomes comparable to intravenous treatment. Investigators observed equivalent amyloid plaque reduction while maintaining similar rates of amyloid-related imaging abnormalities (ARIA-E) and no increase in isolated ARIA-H compared with intravenous administration. The new formulation also allows patients to switch between intravenous and subcutaneous administration during treatment, providing physicians with greater flexibility to tailor therapy according to individual patient needs. Healthcare experts believe this flexibility will reduce reliance on infusion facilities, preserve hospital resources for patients requiring intravenous therapy, and simplify treatment logistics for thousands of individuals diagnosed with early Alzheimer’s disease. The approval reflects the growing emphasis on improving patient convenience while maintaining high standards of clinical efficacy and safety in neurodegenerative disease management.
Advertisement
Eisai Advances the Future of Alzheimer’s Therapy
The approval of LEQEMBI IQLIK further strengthens Eisai’s leadership in Alzheimer’s disease innovation and supports the ongoing transition toward precision medicine and patient-centered neurological care. As pharmaceutical research expands beyond amyloid-targeted therapies into additional disease mechanisms, more convenient drug delivery methods are expected to facilitate combination treatment strategies, personalized therapeutic approaches, and broader access to disease-modifying medicines. Eisai and Biogen continue collaborating globally to advance lecanemab while expanding regulatory approvals across international markets. With LEQEMBI already approved in more than 50 countries and regions, the addition of subcutaneous initiation dosing represents another significant milestone in improving treatment accessibility, enhancing healthcare efficiency, and supporting long-term management of Alzheimer’s disease. The FDA’s latest approval marks an important step toward making innovative therapies easier to administer while helping transform the future landscape of neurodegenerative disease care.
Source: Eisai, Biogen press release
